What is not an appropriate response to a protocol violation: reducing sample size, documenting and reporting to Institutional Review Board (IRB), or addressing participant safety concerns?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The correct answer is C, as reducing the study sample size in order to minimize future protocol violations is not an appropriate response to a protocol violation occurrence. When a protocol violation occurs during a clinical trial, proper responses include:

  • Documenting the violation and any corrective actions taken
  • Reporting the violation to the Institutional Review Board (IRB) 1
  • Immediately addressing any participant safety concerns related to the violation

These steps ensure transparency, regulatory compliance, and participant protection. Reducing the sample size, however, would compromise the scientific validity and statistical power of the study, potentially invalidating the research findings. It also fails to address the root cause of the violation and could be seen as an attempt to hide problems rather than properly managing them. Protocol violations should be managed through improved training, enhanced monitoring procedures, or protocol amendments if necessary, while maintaining the integrity of the study design, as emphasized by the SPIRIT 2013 statement 1.

In the context of clinical trials, adherence to protocol is crucial for ensuring the reliability and generalizability of the results, and any deviations from the protocol should be handled in a way that prioritizes participant safety and the integrity of the study. The Heart Failure Association of the European Society of Cardiology also highlights the importance of adapting IRB policies to support clinical trials during extraordinary circumstances, such as the COVID-19 pandemic, while maintaining the principles of good clinical practice 1.

Therefore, the focus should be on addressing the protocol violation in a transparent and compliant manner, rather than altering the study design in a way that could compromise its validity.

From the Research

Protocol Violation Response

The following options are potential responses to a protocol violation occurrence:

  • Document the violation and corrective action
  • Report the violation to the affiliated IRB
  • Immediately address any concerns regarding participant safety related to the violation

Inappropriate Response

The option that is NOT an appropriate response to a protocol violation occurrence is:

  • Reduce the study sample size in order to minimize future protocol violations

There are no research papers provided that directly address the appropriate response to a protocol violation occurrence in the context of GCP certification 2, 3, 4, 5, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.